# Safety and Immunogenicity Study in Young Adults the Meningococcal Serogroup C Vaccine Produced by Bio-Manguinhos

> **NCT01889836** · PHASE1 · COMPLETED · sponsor: **The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)** · enrollment: 60 (actual)

## Conditions studied

- Meningitis, Meningococcal, Serogroup C

## Interventions

- **BIOLOGICAL:** 'MenCC-Bio'
- **BIOLOGICAL:** MENJUGATE

## Key facts

- **NCT ID:** NCT01889836
- **Lead sponsor:** The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2015-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01889836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01889836, "Safety and Immunogenicity Study in Young Adults the Meningococcal Serogroup C Vaccine Produced by Bio-Manguinhos". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01889836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*